1. 2010 A genetic variant in RASSF1A, a key regulator of HIPPO pathway, predicts survival in two independent cohorts of mCRC patients treated with cetuximab-based chemotherapy. (September 2015) Authors: Sebio, A.; Stintzing, S.; Heinemann, V.; Zhang, W.; Sunakawa, Y.; Ichikawa, W.; Tsuji, A.; Takahashi, T.; Parekh, A.; Yang, D.; Cao, S.; Ning, Y.; Stremitzer, S.; Matsusaka, S.; Okazak, S.; Barzi, A.; Lenz, H.J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S331 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade. (31st December 2022) Authors: Kofla, G.; Radecke, C.; Frentsch, M.; Walther, W.; Stintzing, S.; Riess, H.; Bullinger, L.; Na, I-K. Journal: Oncoimmunology Issue: Volume 11:Number 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306). (October 2017) Authors: Modest, D.P.; Ricard, I.; Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Kahl, C.; Seipelt, G.; Kullmann, F.; Scheithauer, W.; Moehler, M.; Westphalen, C.B.; Holch, J.W.; von Einem, J.C.; Held, S.; Heinemann, V. Journal: European journal of cancer Issue: Volume 84(2017) Page Start: 262 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5‐FU/LV plus irinotecan or irinotecan plus oxaliplatin as first‐line treatment (FIRE 1‐trial). Issue 3 (18th September 2015) Authors: Stahler, A.; Heinemann, V.; Giessen‐Jung, C.; Crispin, A.; Schalhorn, A.; Stintzing, S.; Fischer von Weikersthal, L.; Vehling‐Kaiser, U.; Stauch, M.; Quietzsch, D.; Held, S.; von Einem, J.C.; Holch, J.; Neumann, J.; Kirchner, T.; Jung, A.; Modest, D.P. Journal: International journal of cancer Issue: Volume 138:Issue 3(2016:Feb. 01) Page Start: 739 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer. (April 2016) Authors: Sunakawa, Y.; Bekaii-Saab, T.; Stintzing, S. Journal: Cancer treatment reviews Issue: Volume 45(2016) Page Start: 97 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). (January 2019) Authors: Holch, J.W.; Ricard, I.; Stintzing, S.; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Heintges, T.; Kahl, C.; Kullmann, F.; Scheithauer, W.; Moehler, M.; Jelas, I.; Modest, D.P.; Westphalen, C.B.; von Einem, J.C.; Michl, M.; Heinemann, V. Journal: European journal of cancer Issue: Volume 106(2019) Page Start: 115 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗